Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

Abstract Background Women with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) experience more frequent and severe angioedema attacks compared with men. Fluctuations in female sex hormones can influence HAE attack frequency and severity. Subcutaneous C1-INH (C1-INH [SC]) is indicate...

Full description

Bibliographic Details
Main Authors: Donald S. Levy, Henriette Farkas, Marc A. Riedl, Florence Ida Hsu, Joel P. Brooks, Marco Cicardi, Henrike Feuersenger, Ingo Pragst, Avner Reshef
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Hereditary angioedema
Female
Women
HAEGARDA
Estrogen
C1-inhibitor
Online Access:https://doi.org/10.1186/s13223-020-0409-3

Internet

https://doi.org/10.1186/s13223-020-0409-3

Similar Items